Meta-analysiscited by the Tayebat archivefull text checked★ key study A-WHT-02 in-depth review
Whole grains and lower risk of heart disease and death
Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies.
Overview
Aune D et al.. BMJ 2016 · PMID 27301975 · DOI 10.1136/bmj.i2716
Each 3 servings/day of whole grains linked to 17% lower mortality and 19% lower CHD.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Summarise studies on whole grains and disease
- How was the study done?
Dose-response meta-analysis
- How many people, animals or samples were studied?
45 cohort studies; up to about 705,000 participants and 100,726 deaths (all-cause mortality analysis).
- What was actually found?
Whole grains linked to less disease; refined grains neutral
- How large was the observed effect?
RR 0.83 mortality per 90 g/day
- What do the results mean in everyday life?
Choosing whole grains is linked to better health
- What are the study's limitations?
Observational data; high heterogeneity for total mortality; no registered protocol; substitution not studied.
- What does it say about Elawady's specific claim?
Supports whole-grain preference, not 'white flour is poison'
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Cannot prove cause, cannot quantify the effect of swapping refined for whole grains, and shows no harm from refined grains.
Scientific in-depth review
1. Full reference
- Authors
- Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T
- Journal
- BMJ
- Year
- 2016
- Identifier
- PMID 27301975 DOI 10.1136/bmj.i2716 · PMC4908315
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Funding: Olav og Gerd Meidel Raagholt's Stiftelse for Medisinsk Forskning, Central Norway RHA-NTNU liaison committee, Imperial College NIHR Biomedical Research Centre; funders had no role. ICMJE: no support for the submitted work and no relevant financial relationships.
2. Research question
Dose-response between whole grain/specific grains and CVD, cancer and mortality
3. Study design and population
- Study design
- Meta-analysis – Systematic review and dose-response meta-analysis of prospective cohort studies (PRISMA-reported; no registered protocol reported)
- Population
Participants of prospective cohorts
- Country
20 studies from Europe, 16 from the US, 9 from Asia
- Period
PubMed and Embase from inception to 31 May 2014, updated to 3 April 2016
- Sample size
45 cohort studies (64 publications); e.g. CHD 7,068 cases/316,491 participants; CVD 26,243 cases/704,317; total cancer 34,346 deaths/640,065; all-cause mortality 100,726 deaths/705,253
- Inclusion and exclusion criteria
Prospective studies reporting adjusted RRs with 95% CIs for whole grains or specific grain types and CHD, stroke, CVD, total cancer, all-cause or cause-specific mortality; >=3 intake categories or continuous estimate for dose-response; excluded studies listed (appendix table S2)
4. Methods and endpoints
- Exposure / intervention
Whole grain intake per 90 g/day; specific grain types
- Comparator
Lower intake
- Endpoints
CHD, stroke, CVD, total cancer, all-cause and cause-specific mortality
- Statistical methods
DerSimonian-Laird random effects; Greenland-Longnecker linear and restricted cubic spline non-linear dose-response; I2 heterogeneity; subgroup/meta-regression (incl. adjustment for confounders, study quality); influence analysis; Egger's test; Newcastle-Ottawa quality scores (mean 7.7-7.9 of 9)
5. Actual results
- Results
Per 90 g/day whole grain: CHD RR 0.81 (95% CI 0.75-0.87; I2 9%; 7 studies); stroke 0.88 (0.75-1.03; I2 56%); CVD 0.78 (0.73-0.85; I2 40%); total cancer 0.85 (0.80-0.91; I2 37%); all-cause mortality 0.83 (0.77-0.90; I2 83%; 11 studies); respiratory 0.78 (0.70-0.87); diabetes 0.49 (0.23-1.05; I2 85%); infectious 0.74 (0.56-0.96); nervous system 1.15 (0.66-2.02); non-CVD non-cancer 0.78 (0.75-0.82). High vs low: all-cause 0.82 (0.77-0.88), CVD 0.84 (0.80-0.87). Risk reductions up to 210-225 g/day; non-linear with steeper reductions at lower intakes. Little evidence of association for refined grains, white rice, total rice or total grains; refined grains showed weak inverse (not positive) associations with total cancer and mortality in some dose-response analyses. Egger's test: no small-study bias for CHD, CVD, cancer, mortality; some indication for stroke (P=0.01).
- Absolute risks
not reported
- Authors' conclusion
Whole grain intake is associated with reduced risk of CHD, CVD, total cancer and mortality from all causes, respiratory disease, infections, diabetes and non-CVD non-cancer causes; supports guidelines to increase whole grain intake (benefits up to 210-225 g/day).
6. Strengths
- Comprehensive search with listed exclusions
- Linear and non-linear dose-response analyses
- Quality assessment (Newcastle-Ottawa) and subgroup by confounder adjustment
- Publication-bias assessment
- Large number of cases and participants
7. Weaknesses
- Observational primary studies; healthy-user and socioeconomic confounding acknowledged
- High heterogeneity for all-cause mortality (I2 83%) and diabetes mortality
- No registered protocol; single-author extraction checked by a second author (not fully independent duplicate extraction); screening process not described as duplicate
- Heterogeneous definitions and measurement of whole grain
- Few studies for refined grains and grain subtypes
- Did not analyse substitution of refined by whole grains
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Single-reviewer AMSTAR 2-oriented appraisal based on the full text; critical item 2 not met and items 4/9 partial, so overall confidence would be rated 'low' under strict AMSTAR 2 rules. Not formal (needs two independent reviewers).
| Domain | Judgement | Rationale |
|---|---|---|
| Item 2 (critical): protocol established a priori | high | No protocol or registration reported. |
| Item 4 (critical): comprehensive search | some concerns | PubMed and Embase plus reference lists; no grey literature or trial registries (partial yes). |
| Items 5/6: duplicate selection and extraction | some concerns | Extraction by one author checked by another; duplicate screening not described. |
| Item 7 (critical): list of excluded studies with justification | low | Excluded studies listed in appendix table S2. |
| Item 9 (critical): RoB assessment of included studies | some concerns | Newcastle-Ottawa scale used (partial yes); not a domain-based RoB tool. |
| Item 11 (critical): appropriate meta-analytic methods | low | Random effects with standard dose-response methods. |
| Item 13 (critical): RoB accounted for in interpretation | some concerns | Subgroups by quality and confounder adjustment; confounding discussed, but conclusions use causal-leaning language ('beneficial effects'). |
| Item 15 (critical): publication bias | low | Egger's test and funnel plots; discussed. |
| Item 16: conflicts of interest | low | Funding and COI reported; no relevant interests. |
Full-text review (25 October 2026): Added regional distribution, cases/participants per outcome, high-vs-low estimates, non-linearity, Newcastle-Ottawa scores, Egger results, funding/COI from full text, refined grains weakly inverse in some analyses; full AMSTAR 2 item assessment (no protocol; overall unchanged: some concerns).
9. Assessment of the statistical interpretation
Relative risks per 90 g/day increment from observational cohorts; consistent and precise for CHD/CVD/cancer, heterogeneous for all-cause mortality. These are not substitution estimates; refined grains were not associated with higher risk.
10. Relevance to the specific claim
Supports C-WHT-04; limits C-WHT-03.
11. Independent contrary findings
None for direction.
12. Transferability to Germany and Europe
High (many European cohorts).
13. Overall methodological judgement
Strong evidence for whole-grain benefit; neutral for refined grains.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | some concerns |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | partly correct but over-interpreted |
14. Open questions
Causality; substitution effects.
15. Linked fact checks
- Replacing refined grains with whole grains lowers all-cause mortality by 17% and coronary heart disease by 19%, while refined grains offer no protective benefit (archive interpretation of Aune 2016). – Studies supporting the claim
- Heavy intake of refined grains (white bread etc.) is associated in the largest population studies with higher mortality and major cardiovascular disease (archive: PURE, +27% mortality, +33% major cardiovascular events at >=350 g/day). – Studies contradicting or limiting the claim
- Freekeh and corn (maize) are allowed staple carbohydrates. – Studies supporting the claim
- Commercial 'brown' or whole-wheat toast (brand named: Rich Bake) is allowed because, although it contains white flour and gluten, it is made in an easy-to-digest form that does not stick in the colon. – Studies with mixed or unclear results
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
45 studies, ~700,000 people: swapping refined grains for whole grains lowered death from heart disease, cancer and any cause by 17-19%, while refined grains showed no protective benefit.
- A. What was actually studied?
Whole-grain intake dose-response with outcomes.
- B. What did the authors find?
Per 90 g/day whole grain: all-cause mortality RR 0.83, CHD 0.81, CVD 0.78, cancer 0.85; little evidence of association (and some weak inverse associations) for refined grains, white rice, total grains.
- C. What conclusions do the authors themselves draw?
Supports increasing whole grain intake.
- D. What does the archive derive from it?
Presents the results as effects of swapping refined for whole grains.
- E. Is this derivation scientifically justified?
Partly. Numbers (17% lower mortality, 19% lower CHD per 90 g/day) are correctly taken, but the study analysed increments of whole grain intake, not 'replacing refined with whole grains', and associations are observational; 'refined grains offer no protective benefit' omits that refined grains were not linked to harm and showed weak inverse associations in some analyses.
- Adequacy of the interpretation (by the archive)
- partly correct but over-interpreted